
|Articles|October 1, 2005
- Volume 0 0
Diabetes Product Charts
Advertisement
Articles in this issue
over 20 years ago
A Pharmacist's Guide to OTC Therapy: Ocular Care Productsover 20 years ago
Dangerous Liaisons: Schizophrenia and Diabetesover 20 years ago
Tarceva Extends Lung Cancer Survivalover 20 years ago
Inhaled Morphine Aids Cancer-related Dyspneaover 20 years ago
Diuretic Best BP Therapy for African Americansover 20 years ago
A Pharmacist's Guide to OTC Therapy: Diabetic Foot Care Productsover 20 years ago
New Drug Blocks Out AIDS Virusover 20 years ago
Viagra Ingredient Has Another Useover 20 years ago
GUEST COMMENTARY: FIGHTING THE NEW PHARMACOPHOBIAAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADA 2026: Factors Associated With GLP-1 RA Nonresponse in T2D—and What Pharmacists Should Screen For
2
ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk
3
ADA 2026: Optimized Inhaled Insulin Dosing Outperforms Subcutaneous Analogs for Postprandial Glucose in T1D
4
The Hidden Reimbursement Crisis in Medicare’s Drug Price Negotiation Program
5






































































































































